Home About Us Services Markets Online Trading Back Office Contact Us Download Mutual Fund
Your are on :  Markets   |  News Analysis    |  Corporate News   |Detailed News   
Back
Alembic Pharmaceuticals announces acquisition of Utility Therapeutics
03-Jul-25   09:15 Hrs IST

Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acquired Utility Therapeutics for a consideration of $12 million in staggered manner over period of time, depending on milestones achieved.

Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI).

-'Pivya' is an FDA approved product to treat uncomplicated UTIs in the US market.

-'MEC' is a product in development for treatment of the complicated UTIs in the US market.

As a product development company they have minimal turnover in last 3 years.

Powered by Capital Market - Live News

Product Disclaimer Mandatory Information Privacy Policy Careers Risk disclosures Feedback Scores 2.0 Member Bank Details
"Investor Grievance" Mail your Grievance to info@lalkar.in
Important Links:   SEBI  |  NSE  |  BSE  |  MCX-SX  |  MCX   |   NCDEX  |  NSDL  |  CDSL  |  FMC   |   CDSL E-Voting  |  SMART ODR|  Saa₹thi  |  View Client Collateral Details  |  
Vernacular Languages  |  Online Freezing/Blocking Account  |  Advisory for Investor
SEBI REGISTRATION NOS - BSE CASH: INZ000269434  |  BSE FNO: INZ000269434  |  NSE CASH: INZ000269434  |  NSE FNO: INZ000269434  |  NSE CD: INZ000269434  |  MSEI CASH: INZ000269434   |   MSEI FNO: INZ000269434   |   MSEI CD: INZ000269434
AMFI NO : ARN- 19226
2010 © Lalkar Group. All rights reserved Designed, developed & powered by CMOTS Infotech(ISO 9001:2015 certified)